SCHEMBL16237619

SCHEMBL16237619

COC(=O)c1c(CN2C3COC[C@H]2CC(CC(=O)O)C3)nc(-c2nccs2)nc1-c1ccc(F)cc1Cl

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 1/20 0.36
▸ CCR3 P51677 1/20 0.36
▸ KCNH2 Q12809 5/20 0.36
▸ TP53 P04637 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ CCNT1 O60563 4/20 0.33
▸ CDK9 P50750 4/20 0.33
▸ HDAC3 O15379 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ LTA4H P09960 1/20 0.32
▸ CDC7 O00311 1/20 0.32
▸ DBF4 Q9UBU7 1/20 0.32
▸ PDCD1 Q15116 1/20 0.31
▸ CD274 Q9NZQ7 1/20 0.31
▸ HCRTR1 O43613 5/20 0.31
▸ HCRTR2 O43614 5/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16237492 0.93 KCNH2 (0.42) CYP2D6CCR3KCNH2HDAC3HDAC1
SCHEMBL16237122 0.93 CYP2D6 (0.35) CYP2D6CCR3KCNH2TP53MAPT
SCHEMBL16237458 0.92 KCNH2 (0.35) CYP2D6CCR3KCNH2TP53MAPT
SCHEMBL16237808 0.92 CYP2D6 (0.36) CYP2D6CCR3KCNH2CCNT1CDK9
SCHEMBL16237558 0.92 CYP2D6 (0.38) CYP2D6CCR3KCNH2TP53MAPT
SCHEMBL16236918 0.91 CYP2D6 (0.38) CYP2D6CCR3KCNH2TP53MAPT
SCHEMBL16237555 0.90 CYP2D6 (0.41) CYP2D6CCR3KCNH2TP53MAPT
SCHEMBL16237752 0.89 CYP2D6 (0.36) CYP2D6CCR3KCNH2TP53MAPT
SCHEMBL16237518 0.89 KCNH2 (0.37) CYP2D6CCR3KCNH2TP53MAPT
SCHEMBL16237685 0.89 KCNH2 (0.38) CYP2D6CCR3KCNH2TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2997032-A1 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2016-03-23 — — EP claimed
WO-2014184328-A1 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2014-11-20 — — WO claimed
EP-2997032-A1 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2016-03-23 — — EP disclosed
WO-2014184328-A1 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2014-11-20 — — WO disclosed
Send feedback